NF1 and glioma: MEKi trametinib therapy of NF1 associated high grade gliomas is reported only in single NF1 adult cases: in a 24-year-old male with NF1 and treatment-refractory glioblastoma and in a 19-year-old male with NF1 and a recurrent mesencephalic glioblastoma [54, 55].